Prothrombotic markers in atrial fibrillation: What is new?

European Heart Journal

Volumn 22, Issue 18, 2001, Pages 1635-1639

  Al Saady, N M ^a   Sopher, M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PADGEM PROTEIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR; WARFARIN;

CONTROLLED STUDY; EDITORIAL; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; FIBRINOGEN; HUMANS; P-SELECTIN; VON WILLEBRAND FACTOR;

EID: 0034832785     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2759     Document Type: Editorial

References (36)

1. Atrial fibrillation: A review of mechanism, etiology, and therapy
2. Epidemiologic features of atrial fibrillation. The Framingham Study
3. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study
4. Atrial fibrillation and stroke: New ideas, persistent dilenunas
5. Thoracoscopic obliteration of the left atrial appendage: Potential for stroke reduction
6. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
7. Plasma von Willebraud factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function
8. Prothrombin fragment Fl+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation
9. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation
10. Fibrin D-dimer and b-thromboglobulin as markers of thrombogensis and platelet activation in atrial fibrillation
11. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: Rabbit experimental model
12. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide
13. GMP-140, a platelet a-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies
14. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine and thrombin: A juxtacrine system for adhesion and activation of neutrophils
15. The effects of atrial fibrillation on atrial pressure-volume and flow relationships
16. Chronic rapid atrial pacing: Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation
17. Atrial enlargement as a consequence of atrial fibrillation: A prospective echocardiographic study
18. The left atrial appendage: Structure, Function and Role in Thromboembolism
19. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterisation by simultaneous transesophageal echocardiography
20. The relationship between atrial thromboembolism, endocardial expression of von Willebrand Factor and atrial macrophage infiltration in the fibrillating atrium
21. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications of atrial fibrillation. The Copenhagen AFASAK Study
22. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomised controlled trials
23. Atrial fibrillation and stroke: Three new studies, three remaining questions
24. Trial of different intensities of anticoagulation in patients with prosthetic heart valves
25. Thromboembolic risk and late survival after mitral valve replacement with the St. Jude Medical Valve
26. Anticoagulation in atrial fibrillation: Does efficacy in clinical trials translate into effectiveness in practice?
27. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy
28. Low dose aspirin does not lower in vivo platelet activation in healthy smokers
29. Impaired left atrial mechanical function after cardioversion: Relationship to the duration of atrial fibrillation
30. Short-term effect of atrial fibrillation on atrial contractile function in humans
31. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in nonrheumatic atrial fibrillation
32. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation
33. Activation of the haemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation
34. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: Effects of cardioversion to sinus rhythm
35. Plasma fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: Evidence of intermediate levels of intravascular thrombogenesis
36. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?